The effect of ketanserin on cerebral blood flow and oxygen metabolism in healthy volunteers.
The effect of the anti-hypertensive agent ketanserin on average global cerebral blood flow (CBF) and average global cerebral oxygen metabolism (CMRO2) was examined in 8 healthy volunteers. CBF and CMRO2 were measured with the Kety-Schmidt technique before ketanserin administration (baseline) and after administration of 2 different doses of ketanserin intravenously (dose I: 10 mg bolus and an infusion of 6 mg/h; dose II: 20 mg bolus and an infusion of 20 mg/h). Baseline CBF and CMRO2 were 60 and 3.6 ml/100 g/min, respectively, and were not changed by administration of ketanserin dose I. During administration of dose II, however, CBF fell to 52 ml/100 g/min (p = 0.05) and CMRO2 was reduced to 3.2 ml/100 g/min (p < 0.05). We conclude that when administered in a high dose, ketanserin has the ability to depress cerebral oxygen metabolism, but when administered in a clinically relevant dose ketanserin does not influence average global CBF or average global CMRO2. Ketanserin could be a safe antihypertensive drug in neuroanaesthesia or in the neuro-intensive care unit.
Olsen
K S
KS
Department of Anaesthesia, Rigshospitalet, Copenhagen, Denmark.
Madsen
P L
PL
Børme
T
T
Schmidt
J F
JF
D000328:Adult; D001783:Blood Flow Velocity / Q000187:drug effects; D001921:Brain / Q000098:blood supply*; D004305:Dose-Response Relationship, Drug; D004734:Energy Metabolism / Q000187:drug effects; D005260:Female; D006706:Homeostasis / Q000187:drug effects; D006801:Humans; D007262:Infusions, Intravenous; D007650:Ketanserin / Q000494:pharmacology*; D008297:Male; D010101:Oxygen Consumption / Q000187:drug effects*; D012039:Regional Blood Flow / Q000187:drug effects; D014980:Xenon Radioisotopes
D014980:Xenon Radioisotopes; D007650:Ketanserin